Why does the fix take so long to show up?
Because a buyer does not underwrite the current month. They underwrite a trailing period, and the current standard for a middle-market process is at least thirty-six months of clean, normalized monthly financials (Capstone Partners, Capital Markets Update, 4 June 2026). Concentration is measured inside that window, which means a business that fixed the problem last quarter still presents three years of data in which the problem is present for most of the period.
There is a second lag on top of the first. New revenue is not credited at full weight when it is new. A customer signed nine months ago with no renewal history is a prospect in the buyer's model, not a diversification. What converts it into evidence is a renewal, a second year at similar or higher volume, and a contract with a term on it.
So the honest timeline has three stages, not one. Win the revenue. Hold it long enough for the trailing average to move. Then hold it long enough again for the newest cohort to have renewed. That is the difference between the date an owner fixes the business and the date a buyer can see it fixed, and it is usually two to three years wide.
How much has to change for the ratio to move?
More than owners expect, because the denominator moves with the numerator. This is arithmetic rather than a market observation, and it is worth doing on a napkin before committing to a plan.
Take a business with $10m of revenue and a top customer at 40%, so $4m. Holding that customer flat, getting concentration to 25% requires total revenue of $16m, which means the rest of the business has to grow from $6m to $12m. The concentration ratio falls by 15 percentage points and the other revenue has to double to do it. Reaching 30% requires $13.3m of total revenue, still a 55% increase in the non-concentrated base.
That is why the plausible strategies are narrow. Growing the base is slow. Deliberately shrinking the large customer trades revenue and profit for a ratio, which a buyer values only if the profit lost was low quality. Acquiring revenue is the fastest route and introduces its own diligence problems, since a buyer will look through the acquisition to the underlying concentration anyway.
None of this argues against fixing it. It argues for starting earlier than the sale date suggests, and for being specific about how many dollars of new revenue the target ratio actually requires rather than committing to diversify in the abstract.
What does the calendar look like backwards from a sale date?
Layered, and the layers do not run in parallel. Exit preparation is advised to begin twelve to twenty-four months before a sale, and assets not already in preparation by mid-2026 are structurally 2027 and 2028 transactions (EY, Global Private Equity Exit Readiness Study 2026, published 28 July 2026). The financial record needs about thirty-six months of clean monthly data behind it (Capstone Partners, 4 June 2026). And exit planning that actually changes the price is described as starting three to five years ahead, with customer base diversification named as a prerequisite for the premium (Acquisition Stars, exit planning analysis, April 2026).
Stacked, that puts a concentration program at the outermost ring. It has to start before the financial record it needs to appear in, which has to start before the preparation phase, which has to start before the process. An owner targeting a sale in 2029 is at the correct starting point for a diversification program in 2026. An owner targeting 2027 is not, and the useful conversation is a different one.
The table below sets that out as a single backwards calendar. It is a planning frame rather than a rule, and the ranges come from the sources named against each row.
| Lead time before sale | What has to be underway | Source and date |
|---|---|---|
| Three to five years | Exit planning, with customer diversification named as a prerequisite for the price premium | Acquisition Stars, April 2026 |
| About three years | The clean, normalized monthly financial record a buyer will underwrite | Capstone Partners, 4 June 2026 |
| Two to three years | New revenue won early enough to have renewed and to have moved the trailing average | Trailing-period arithmetic, this article |
| Twelve to twenty-four months | Formal exit preparation. Assets not in preparation by mid-2026 are structurally 2027 and 2028 transactions | EY, 28 July 2026 |
| Weeks to months | The contract, renewal and relationship evidence package, where the ratio can no longer be moved | Our own mandate practice |
“The cruel part of the arithmetic is that the owner who most needs to diversify is usually the one with the least time to do it, because concentration and the urge to sell tend to arrive together. Starting three years early is cheap. Starting one year early mostly buys you a story the buyer will not price.”
What is the cure reported to be worth?
The published evidence is thinner than the confidence with which it is usually quoted, and it deserves to be labelled carefully. The most-cited illustration models a company that diversified its customer base alongside churn and lifetime-value improvements and sees its multiple expand from 4.2x recurring revenue to 6.1x, a 45% increase in enterprise value (Axial and Solganick, 2026 SaaS Multiples Guide, January 2026). That is a modelled scenario, not a completed transaction, and it bundles diversification with two other improvements, so it cannot be read as the price of concentration alone.
The broader range is consistent in direction. A top customer at 20% to 30% of revenue is reported to compress valuation by 10% to 20%, with buyers demanding earnouts or holdbacks above that (Livmo, February 2026), and businesses with high concentration in recurring-revenue categories are reported to land multiples 20% to 30% below diversified peers (Software Equity Group research, cited by HumanR, April 2026).
We have set out the thresholds, the published haircut ranges and the mechanism by which bidders are gated out separately, in the piece on why concentration removes bidders rather than lowering the price. The point that belongs here is different. Whatever the cure is worth, it is only worth it if it lands inside the trailing period a buyer will look at, which is a scheduling question rather than a valuation one.
What if there is no time left?
Then the work changes from moving the ratio to documenting the risk, which is faster and is frequently skipped. Concentration is priced on the assumption that the relationship could end without warning, and the assumption is not unreasonable: two manufacturing businesses were withdrawn from live sale processes in the first half of 2025 after each lost a single customer representing more than half of revenue (FOCUS Investment Banking, July 2025).
What moves a buyer off the worst case is evidence that already exists and is rarely assembled. Contract term and notice provisions, renewal and pricing history across several cycles, the number and seniority of relationships inside the customer, switching costs, sole-source or specified-in status, and the share of that customer's own category spend the business holds. That package can be built in weeks and it addresses the specific fear rather than arguing with the discount.
The second option is to change the buyer list rather than the business. Concentration is a policy constraint for financial buyers and frequently not one for a strategic acquirer already selling to the same customer, or one that wants that account specifically. That is a decision about who gets approached, made before launch.
The third is to accept the structure. Where concentration cannot be cured or documented away, the market bridges it with contingent consideration, and 35% of the smallest lower-middle-market deals already carry an earnout (SRS Acquiom, 5 June 2026). Accepting that knowingly, with the contingent portion priced at a discount, is a legitimate outcome. Discovering it at the letter of intent is not.
As of August 2026
Sources: Capstone Partners, Capital Markets Update, 4 June 2026, for the thirty-six month normalized monthly financial standard; EY, Global Private Equity Exit Readiness Study 2026, published 28 July 2026, surveyed February to April 2026, for the exit preparation runway; Acquisition Stars, exit planning analysis, April 2026, for the three to five year planning horizon and the naming of diversification as a prerequisite, carried as a directional estimate from an exit-planning publication rather than an audited series; Axial and Solganick, 2026 SaaS Multiples Guide, January 2026, for the modelled expansion from 4.2x to 6.1x recurring revenue, which is a modelled scenario bundling diversification with churn and lifetime-value improvements and is not a completed transaction; Livmo, February 2026, for the reported 10% to 20% compression at a top customer of 20% to 30%; Software Equity Group research, cited by HumanR, April 2026, for recurring-revenue businesses; FOCUS Investment Banking, July 2025, for the two manufacturing businesses withdrawn from live processes in the first half of 2025, labelled as a 2025 observation; SRS Acquiom, 2026 M&A Deal Terms Special Report: Lower Middle-Market Deals, 5 June 2026, for earnout prevalence at the smallest end. The thresholds at which buyers are gated out, and the published haircut ranges, are set out in a separate article on this site and are not restated here. No source publishes a measured time-to-effect on concentration metrics; the arithmetic in this article is worked from the trailing-period convention and is shown so it can be checked.